Compare Amylx Pharmaceuticals Inc (AMLX) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Freshworks Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while Freshworks Inc trades at $11.69 (market cap $3.31B). The key difference: Freshworks Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FRSH | |
|---|---|---|
Market Cap | $2.64B | $3.31B |
Sector | Health | Technology |
52-Week High | $24.19 | $13.97 |
52-Week Low | $7.82 | $6.88 |
Enterprise Value | $2.39B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Freshworks (FRSH) trades at $11.98, up 1.18% with bullish technical signals and strong fundamentals. The company reported Q2 2026 revenue growth of 16% year-over-year, achieving its first GAAP profitability quarter with $3.2 million net income. Recent FedRAMP designation and Gartner leadership recognition highlight strategic progress. Analyst consensus shows 50% buy ratings with a $16.50 price target, suggesting 38% upside potential.
The outlook remains positive with accelerating revenue growth and improved profitability, though elevated P/E and EV/EBITDA ratios warrant caution. Key risks include competitive pressures in SaaS and execution challenges. Current momentum supports continued appreciation toward analyst targets, making FRSH attractive for growth-oriented investors despite valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
